Glenmark Pharma signs agreement with Grandpharma
Glenmark Pharmaceuticals on Wednesday announced that its Swiss subsidiary, Glenmark Specialty SA, has entered into an exclusive licensing agreement wi06-02-2019
06-02-2019
Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Glenmark Pharmaceuticals enters into an Exclusive License Agreement with Grandpharma (China) Co. Ltd. for commercializing Investigational Seasonal Allergic Rhinitis Nasal Spray Ryaltris in China06-02-2019
Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Enclosed please find herewith the details of Earnings Call slated for Friday,February 15, 2019 at 8:30 a.m. - 9:30 a.m. (IST), for your information and record. Please note that the recording of the call will be available on our website within 24 hours of the call.04-02-2019
Glenmark Pharmaceuticals Ltd - 532296 - Closure of Trading Window
We have to inform you that, pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, a meeting of the Board of Directors will be held on Thursday,February 14, 2019, inter alia, to consider and approve the Unaudited Financial Results of the Company for the Third Quarter and Nine Months ended December 31, 2018. Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from January 1, 2019 to February 16, 2019 (both days inclusive) for the purpose of approval of Unaudited Financial Results for the Third Quarter and Nine Months ended December 31, 2018.01-02-2019
Glenmark Pharmaceuticals Ltd - 532296 - Board Meeting Intimation for Inter Alia, To Consider And Approve The Unaudited Financial Results Of The Company For The Third Quarter And Nine Months Ended December 31, 2018
GLENMARK PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2019 ,inter alia, to consider and approve the Unaudited Financial Results of the Company for the Third Quarter and Nine Months ended December 31, 2018. Further, as per the "Code of Conduct for Prevention of Insider Trading" and pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015 the Company has intimated its Directors and other designated persons regarding the closure of trading window from January 1, 2019 to February 16, 2019 (both days inclusive) for the purpose of approval of Unaudited Financial Results for the Third Quarter and Nine Months ended December 31, 2018.01-02-2019
Glenmark gets USFDA nod for seizure treatment drug
Glenmark Pharmaceuticals has received a tentative nod from the US health regulator for Topiramate extended release capsules, used to treat certain ty24-01-2019
Glenmark Pharmaceuticals Ltd - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Sub: Glenmark Pharmaceuticals receives tentative ANDA approval for Topiramate Extended-Release Capsules, 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg Dear Sir, With reference to the subject mentioned above, kindly find attached media release which is self explanatory. Request you to kindly take the same on record.24-01-2019
Glenmark gets tentative USFDA nod for prostate cancer treatment drug
Glenmark Pharmaceuticals has received a tentative nod from the US health regulator for Abiraterone Acetate tablets, used in the treatment of prostate23-01-2019
GLENMARK PHARMACEUTICALS LTD. - 532296 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Sub: Glenmark Pharmaceuticals receives tentative ANDA approval for Abiraterone Acetate Tablets USP, 250 mg Dear Sir, With reference to the subject mentioned above, kindly find attached media release which is self explanatory. Request you to kindly take the same on record.23-01-2019
Glenmark Pharmaceuticals Ltd - 532296 - Statement Of Investor Complaints For The Quarter Ended December 2018
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 040400 Name of the Signatory :- Harish KuberDesignation :- Company Secretary and Compliance Officer18-01-2019